Exploratory study of prediction marker for efficacy and safety of TBI-1201
Not Applicable
- Conditions
- Refractory solid tumor
- Registration Number
- JPRN-UMIN000033711
- Lead Sponsor
- Immuno-Gene Therapy, Mie University Graduate School of Medicine
- Brief Summary
The clinical data were analyzed in 10 patients. The safety in cohort 2 was confirmed.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
Not having enrolled to TBI-1201 clinical trial
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Cytokine analysis Immune response analysis Image diagnosis data
- Secondary Outcome Measures
Name Time Method